전체 프로그램

ADC 890 · Antibody 4097 · CGT 2985 · 다음 갱신 D-6 · 마지막 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved23 programs
CGTCurated CoreFDAFerring PharmaceuticalsApproved

nadofaragene firadenovec (Adstiladrin, rAd-IFNα/Syn3, nadofaragene firadenovec-vncg)

High-risk BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) · IFNα2b (adenoviral)

#IFN2badenoviral#CGT#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 10Status Approved
AntibodyCurated CorestaleAstraZenecaPhase 3

Tremelimumab (Tremelimumab)

Hepatocellular Carcinoma · Muscle Invasive Bladder Cancer

#MuscleInvasiveBladderCancer#Antibody#Phase3#BioJungboMoa-pick#Popular+4
Trials 195Status Recruiting
AntibodyLimited DatastaleRochePhase 3

atezolizumab (Tecentriq, MPDL3280A, Atezolizumab (MPDL3280A) [TECENTRIQ], an engineered anti-PDL1 antibody)

Bladder Cancer · Bladder Cancer

#BladderCancer#Antibody#Phase3#Popular#monoclonal-antibody+1
Trials 61Status Active
CGTStandard DatabasestaleSPP Pharmaclon Ltd.Phase 2

Recombinant Interferon Alfa (Recombinant Interferon Alfa)

Colorectal Cancer; Kidney Cancer · Bladder Cancer

#BladderCancer#CGT#Phase2#Popular#cell-gene-therapy+5
Trials 59Status Active
ADCStandard DatabasestaleFavrillederuxtecan for metastatic b…Phase 2

Antibody-Drug Conjugate Therapy (Antibody-Drug Conjugate Therapy)

Metastatic Bladder Urothelial Carcinoma; Metastatic Renal Pelvis and Ureter Urothelial Carcinoma · FRα

#FR#ADC#Phase2#Popular#antibody-drug-conjugate+5
Trials 58Status Recruiting
ADCLimited DatastaleMerck Sharp & Dohme LLCPhase 1

sacituzumab govitecan (Trodelvy, Sacituzumab)

Muscle Invasive Bladder Urothelial Carcinoma · Muscle Invasive Bladder Urothelial Carci

#MuscleInvasiveBladderUrothelialC#ADC#Phase1#Popular#antibody-drug-conjugate+2
Trials 56Status Active
ADCLimited DatastaleAstellas Pharma Incvedotin after avelumabPhase 1

Enfortumab (Enfortumab)

Muscle Invasive Bladder Urothelial Carcinoma · Muscle Invasive Bladder Urothelial Carci

#MuscleInvasiveBladderUrothelialC#ADC#Phase1#antibody-drug-conjugate#vedotin+2
Trials 49Status Active
ADCStandard DatabasestaleAstellasPhase 3

EV/P (enfortumab vedotin and pembrolizumab, enfortumab vedotin and pembrolizumab (EV/P))

Advanced Bladder Cancer · Advanced Bladder Cancer

#AdvancedBladderCancer#ADC#Phase3#antibody-drug-conjugate#ADCsandimmunotherapyhavechangedt+1
Trials 47Status Recruiting
AntibodyLimited DatastaleHoffmann-La RochePhase 2

Hu5F9-G4 (Magrolimab, Magrolimab (Hu5F9-G4))

Urothelial Carcinoma; Bladder Cancer · Urothelial Carcinoma

#UrothelialCarcinoma#Antibody#Phase2#monoclonal-antibody#BladderCancer+2
Trials 35Status Active
ADCLimited DatastaleRemeGenPhase 2

disitamab vedotin (Disitamab Vedotin, RC48, Disitamab Vedotin Tislelizumab)

Her2 Overexpressing High-Risk Non-Muscle Invasive Bladder Urothelial Carcinoma · HER2

#HER2#ADC#Phase2#antibody-drug-conjugate#Her2OverexpressingHigh-RiskNon-M+1
Trials 17Status Active
AntibodyLimited DatastaleAkesoPhase 2

Ivonescimab（AK112，a PD-1/VEGF bispecific antibody） (Ivonescimab（AK112，a PD-1/VEGF bispecific antibody）)

Bladder Cancer; Muscle-invasive Bladder Cancer · PD-1

#PD-1#Antibody#Phase2#monoclonal-antibody#BladderCancer+2
Trials 16Status Recruiting
ADCLimited DatastaleALX Oncology Inc.Phase 2

Evorpacept (Evorpacept)

Plasma Cell Myeloma Refractory · Bladder Cancer

#BladderCancer#ADC#Phase2#antibody-drug-conjugate#PlasmaCellMyelomaRefractory+1
Trials 14Status Recruiting
AntibodyLimited DatastaleThe Affiliated Nanjing Drum Tow…Phase 2

Triplizumab (Triplizumab)

Bladder Cancer · Bladder Cancer

#BladderCancer#Antibody#Phase2#monoclonal-antibody#The
Trials 6Status Active
CGTLimited DatastaleCG Oncology, Inc.Phase 2

oncolytic adenovirus expressing GMCSF (oncolytic adenovirus expressing GMCSF)

Bladder Cancer; High Grade · Bladder Cancer

#BladderCancer#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 2Status Discontinued
AntibodyLimited DatastaleBristol Myers SquibbPhase 2

nivolumab (Opdivo, AMVAC + Nivolumab)

Muscle-Invasive Bladder Carcinoma · Muscle-Invasive Bladder Carcinoma

#Muscle-InvasiveBladderCarcinoma#Antibody#Phase2#monoclonal-antibody#Bristol
Trials 1Status Recruiting
ADCLimited DatastaleRemeGenPhase 2

disitamab vedotin (Disitamab Vedotin, RC48, Disitamab Vedotin and Toripalimab)

Muscle Invasive Bladder Cancer; HER2 Expression · HER2

#HER2#ADC#Phase2#antibody-drug-conjugate#MuscleInvasiveBladderCancer+2
Trials 1Status Active
AntibodyLimited DatastaleIkena OncologyPhase 1

nivolumab (Opdivo, IK-175 and nivolumab)

Urothelial Carcinoma; Urothelial Carcinoma Bladder · Urothelial Carcinoma

#UrothelialCarcinoma#Antibody#Phase1#monoclonal-antibody#UrothelialCarcinomaBladder+1
Trials 1Status Active
CGTLimited DatastaleThe Affiliated Hospital of Xuzh…Phase 1

Recombinant oncolytic adenovirus injection solution of VT-101 (Recombinant oncolytic adenovirus injection solution of VT-101)

Non-muscle Invasive Bladder Cancer · Non-muscle Invasive Bladder Cancer

#Non-muscleInvasiveBladderCancer#CGT#Phase1#cell-gene-therapy#CAR-T+2
Trials 1Status Active
ADCLimited DatastaleFudan UniversityPhase 2

Observational Cohort (Sacituzumab Tirumotecan, Sacituzumab Tirumotecan (Observational Cohort))

Bladder Cancer; Metastatic Urothelial Carcinoma · Bladder Cancer

#BladderCancer#ADC#Phase2#antibody-drug-conjugate#MetastaticUrothelialCarcinoma+1
Trials 1Status Recruiting
AntibodyLimited DatastaleJunshi BiosciencesPhase 3

JS001 (Toripalimab, Toripalimab (JS001 ))

Urinary Bladder Neoplasms · Urinary Bladder Neoplasms

#UrinaryBladderNeoplasms#Antibody#Phase3#monoclonal-antibody#Junshi
Trials 1Status Recruiting

1 / 2 pages

← PreviousNext →